

UNCLASSIFIED

AD NUMBER
ADB286736
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 2002. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 28 July 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-00-1-0663

TITLE: Decorin, A Novel Anti-Tumor Agent that Blocks Breast
Cancer Growth

PRINCIPAL INVESTIGATOR: Renato V. Iozzo, M.D.

CONTRACTING ORGANIZATION: Thomas Jefferson University
Philadelphia, Pennsylvania 19107

REPORT DATE: September 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S.
Government agencies only (proprietary information, Sep 02). Other
requests for this document shall be referred to U.S. Army Medical
Research and Materiel Command, 504 Scott Street, Fort Detrick,
Maryland 21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20030227 065

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-1-0663

Organization: Thomas Jefferson University

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Man 1/24/03

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)**2. REPORT DATE**

September 2002

3. REPORT TYPE AND DATES COVERED

Final (1 Sep 00 - 31 Aug 02)

4. TITLE AND SUBTITLEDecorin, A Novel Anti-Tumor Agent that Blocks
Breast Cancer Growth**5. FUNDING NUMBERS**

DAMD17-00-1-0663

6. AUTHOR(S)

Renato V. Iozzo, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Thomas Jefferson University
Philadelphia, Pennsylvania 19107**E-Mail: Iozzo@lac.jci.tju.edu****8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**Distribution authorized to U.S. Government agencies only
(proprietary information, Sep 02). Other requests for this
document shall be referred to U.S. Army Medical Research and
Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.**12b. DISTRIBUTION CODE****13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information)**

Decorin is a prototype member of a family of the so-called small leucine-rich proteoglycans. Recent evidence has shown that decorin down-regulates the growth of a variety of tumor cells including breast carcinoma cells. Specifically, we have previously shown that decorin blocks the ErbB2 activity and, therefore, we believe that this is the mechanism that is utilized by decorin-induced growth inhibition. In the past funded year, we have made an attempt to generate adeno-associated viral vector (AAV2) containing decorin. After several negative attempts, we were successful in generating an AAV1-decorin vector. In preliminary studies, we have shown that this vector is capable of transducing various tumor cell lines and generating decorin. We have requested and obtained a one-year, no cost extension to pursue the AAV1 transduction experiments both in vitro and in vivo, in an animal model of orthotopic breast cancer.

14. SUBJECT TERMS

breast cancer, AAV1-decorin, ErbB2 activity

15. NUMBER OF PAGES

6

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusions.....	4-5
References.....	5
Appendices.....	N/A

INTRODUCTION

Decorin is a member of the small leucine-rich repeat proteoglycan gene family that is associated with collagen and also affects a variety of cellular functions including modulation of growth factors and the growth of tumor cells. We, and others, have previously shown that exogenous decorin or *de novo* expression of decorin can modulate the growth of a variety of tumor cells including breast carcinoma cells (1-5). The central hypothesis, therefore, of this concept award was to generate AAV vector containing decorin and to treat breast carcinoma cells *in vivo* using this method of gene transfer.

BODY OF WORK

In the past year and a half we have been actively working on generating an AAV vector containing the human decorin gene. After unsuccessful attempts to generate an AAV2, we focused our attention on AAV1 and we were able to generate overexpression of decorin in several tumor cell lines, including colon carcinoma and squamous cell carcinoma. However, in part because of the small amount of funding provided by the concept award and, in part, because of the short period of time given, we have not been able to make significant progress in this area of research. We are still attempting to generate a viable animal model of breast carcinoma. We have tested a number of cells and injected into the mammary gland of nude mice and we have not obtained any tumors. These studies have taken a significant amount of time and have precluded making any considerable progress.

KEY RESEARCH ACCOMPLISHMENTS

We were able to generate a vector that could be used in future studies to target breast cancer cells *in vivo*. This vector is based on the latest generation of AAV1 which can considerably induce expression of decorin in breast carcinoma cells and thus, retard the growth of breast carcinoma. Because this vector is stable, there could be effects even at distant sites because the decorin levels in the blood could also increase. Another advantage of this approach is that the vector could potentially be delivered systemically since it generates very little immune reaction.

REPORTABLE OUTCOMES

At this moment there are no reportable outcomes.

CONCLUSIONS

We have demonstrated that it is possible to generate an AAV1 vector containing decorin and that this vector can officially transduce tumor cell lines. These preliminary studies are encouraging and suggest that we will be able to pursue the study of breast tumor cells *in vivo* once we have established a viable animal model. Of importance is that we have recently published a paper in

Oncogene (6) in which we have shown that adeno virus-mediated gene transfer of decorin, a transient expression of decorin, is capable of suppressing tumorigenicity of colon and squamous cell carcinoma. This study is encouraging and suggests that AAV-decorin could have a significant affect in the treatment of breast carcinoma.

REFERENCES

1. Iozzo, R. V. 1998. Matrix Proteoglycans: From molecular design to cellular function. *Annu. Rev. Biochem.* **67**:609-652.
2. Iozzo.R. V., Chakrani,F., Perrotti, D., McQuillan, D. J., Skorski, T., Calabretta, B., and Eichstetter, I. 1999. Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. *Proc. Natl. Acad. Sci. USA* **96**:3092-3097.
3. Santra, M., Mann, D. M., Mercer, E., Skorsky, T., Calabretta, B. and Iozzo, R. V. 1997. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires p21, an inhibitor of cyclin-dependent kinases. *J. Clin. Invest.* **100**:149-157.
4. Iozzo.R. V, Moscatello, D. K., McQuillan,D. J., and Eichstetter, I. 1999. Decorin is a biological ligand for the epidermal growth factor receptor. *J. Biol. Chem.* **274**: 4489-4492.
5. Santra, M., Eichstetter, I., and Iozzo,R. V. 2000. An anti-oncogenic role for decorin: Downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. *J. Biol. Chem.* **275**: 35153-35161.
6. Reed,C.C., Gauldie,J., and Iozzo R.V. 2002. Inhibition of tumorigenicity by adenovirus-mediated gene transfer of decorin. *Oncogene* **21**:3688-3695.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

28 July 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB233865	ADB264750
ADB265530	ADB282776
ADB244706	ADB286264
ADB285843	ADB260563
ADB240902	ADB277918
ADB264038	ADB286365
ADB285885	ADB275327
ADB274458	ADB286736
ADB285735	ADB286137
ADB286597	ADB286146
ADB285707	ADB286100
ADB274521	ADB286266
ADB259955	ADB286308
ADB274793	ADB285832
ADB285914	
ADB260288	
ADB254419	
ADB282347	
ADB286860	
ADB262052	
ADB286348	
ADB264839	
ADB275123	
ADB286590	
ADB264002	
ADB281670	
ADB281622	
ADB263720	
ADB285876	
ADB262660	
ADB282191	
ADB283518	
ADB285797	
ADB269339	
ADB264584	
ADB282777	
ADB286185	
ADB262261	
ADB282896	
ADB286247	
ADB286127	
ADB274629	
ADB284370	
ADB264652	
ADB281790	
ADB286578	